GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today detailed its presence at the EASL Congress™ 2024.
GENFIT accelerates its research in Acute on-Chronic Liver Failure (ACLF)
EF CLIF and GENFIT partnership event
GENFIT will co-host an event with the European Foundation for the Study of Chronic Liver Failure (EF CLIF) to mark the beginning of a research collaboration aimed at advancing the understanding of ACLF. EF CLIF has conducted several large prospective observational studies in large numbers of patients admitted to hospital in Europe and Latin America for acute decompensation of cirrhosis, helping to better understand the onset and progression of ACLF.
https://finance.yahoo.com/news/genfit-present-latest-aclf-research-201000663.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.